Skip to main content

Table 2 Comparison of plasma AGEs levels and plasma sRAGE levels in 52 patients with adult-onset Still’s disease (AOSD), 36 patients with systemic lupus erythematosus (SLE), and 16 healthy subjects (HC)

From: The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still’s disease

AGEs and sRAGE, patient groups

Median (interquartile range)

AGEs levels, μg/mL

 

 Active AOSD (n=30)

16.75 (12.45-24.66)**##§§§

 Inactive AOSD (n=22)

7.02 (5.43-9.01)

 Active SLE (n=25)

14.80 (10.68-21.42)**##§§

 Inactive SLE (n=11)

6.49 (4.40-11.10)

 HC (n=16)

9.80 (4.55-10.83)

sRAGE levels, pg/mL

 

 Active AOSD (n=30)

632.2 (437.8-866.9)**#§§§

 Inactive AOSD (n=22)

858.9 (599.8-1222.2)§

 Active SLE (n=25)

771.6 (553.0-1069.1)*§§

 Inactive SLE (n=11)

1480.0 (892.1-1686.9)

 HC (n=16)

1051.7 (738.2-1468.3)

  1. AGEs: advanced glycation end products; sRAGE: soluble receptor for AGEs.
  2. *p<0.05, **p<0.001, versus HC; #p<0.05, ##p<0.001 versus inactive AOSD;
  3. §p<0.05, §§p<0.005, §§§p<0.001, versus inactive SLE.
  4. Mann-Whitney U test was used for between-group comparison of numerical variables.